| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 6th July 2020 | Jay Venkatesan | 9,310 | Exercise of derivative | $0.65 | $6,051.50 |
| 6th July 2020 | Jay Venkatesan | 12,930 | Exercise of derivative | $1.03 | $13,317.90 |
| 12th June 2020 | Chad A. Mirkin | 10,195 | Open or private sale | $2.83 | $28,851.85 |
| 12th June 2020 | Llc Aurasense | 10,195 | Open or private sale | $2.83 | $28,851.85 |
| 20th May 2020 | Chad A. Mirkin | 49,649 | Exercise of derivative | $0.65 | $32,271.85 |
| 13th March 2020 | David R Walt | 54,064 | Open or private purchase | $16.66 | $900,911.68 |
| 13th March 2020 | David R Walt | 291,066 | Open or private purchase | $1.21 | $352,859.31 |
| 12th March 2020 | David S Snyder | 18,248 | Open or private purchase | $1.40 | $25,591.00 |
| 12th March 2020 | Chad A. Mirkin | 15,000 | Open or private purchase | $1.45 | $21,750.00 |
| 2nd January 2020 | David R Walt | 2,270 | Grant/award etc. | $0.00 |
Exicure
Exicure, Inc. engages in the provision of clinical stage biotechnology company. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.
Ticker: XCUR
Sector: Commercial Services
Industry: Miscellaneous Commercial Services
SEC Central Index Key (CIK): 1698530
Employees:
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $17 M (0%)
Assets, Current: $89 M (-20%)
Property, Plant and Equipment, Net: $4 M (0%)
Other Assets, Noncurrent: $2 M (0%)
Assets: $96 M (-16%)
Long-term Debt, Current Maturities: $0 (-100%)
Accounts Payable, Current: $2 M (-15%)
Accrued Liabilities, Current: $2 M (0%)
Liabilities, Current: $14 M (-53%)
Liabilities: $14 M (-58%)
Common Stock, Value, Issued: $9 Th (0%)
Common Stock, Shares, Issued: $87 M (0%)
Retained Earnings (Accumulated Deficit): $84 M (3%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $338 Th (1151%)
Stockholders' Equity (Parent): $82 M (0%)
Liabilities and Equity: $96 M (-16%)
Revenue: $5 M (-65%)
Research and Development: $7 M (-46%)
General and Administrative Expenses: $2 M (-53%)
Operating Income/Loss: $4 M (13%)
Other Income, net: $79 Th (-88%)
